AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06265779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06265779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06265779 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06265779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
Study NCT04529473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eubacterium hallii
Description: Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
Study NCT04529473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to the active treatment
Study NCT05482932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related physical fitness assessment
Description: Participants will complete several questionnaires and perform multiple health-related physical fitness tests
Study NCT06442761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: Given Subcutaneously (under the skin).
Study NCT06004752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
Study NCT06197399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detethering Surgery
Description: Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
Study NCT06004752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
Study NCT05234177 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth (tablet)
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given intravenously (IV) infusion
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal (IT) chemotherapy
Description: Given intrathecal (IT)
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study NCT06197399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Column Shortening Surgery
Description: Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols.
Study NCT05087823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Challenge
Description: For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
Study NCT05087823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Challenge
Description: For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
Study NCT05087823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Meal Challenge
Description: For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
Study NCT06177067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study NCT05551429 — intervention group
Intervention type: BEHAVIORAL
Intervention: Invitation to the CR
Description: 1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later.
Study NCT05348395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
Study NCT05760430 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PVE+cTACE+Camrelizumab+Apatinib
Description: After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
Study NCT05760430 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: cTACE+Atirizumab+Bevacizumab
Description: After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
Study NCT06183515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash
Description: The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
Study NCT06183515 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash
Description: The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
Study NCT06329518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin
Description: After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
Study NCT06699797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclaim Cochlear Implant
Description: Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
Study NCT06719778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-stage nutritional therapy concept
Description: 1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect.
Study NCT06725212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Water Vapor Thermal Ablation
Description: The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
Study NCT06725212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water Vapor Thermal Ablation
Description: The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
Study NCT06725212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cystoscopy
Description: Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
Study NCT06730360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy without photobiomodulation
Description: This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.
Study NCT06730360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA Pulpotomy with Photobiomodulation (LLLT)
Description: This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
Study NCT06739772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling and Behavior Intervention
Description: Participants in the intervention group will receive HPV self sampling and behavioral intervention
Study NCT06739772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants in the intervention group will receive HPV self sampling and behavioral intervention
Description: Received enhance standard care
Study NCT06740903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h
Description: Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
Study NCT06740903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inj. lignocaine infusion @1-2 mg/kg/h
Description: Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
Study NCT06739824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional Treatment(CI)
Description: Patients receive a corticosteroid injection followed by conventional treatment, such as standard physical therapy exercises focused on range of motion and strengthening, without the specific manual techniques of the Spencer method.
Study NCT06739824 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Spencer Technique (CI)
Description: Patients receive a corticosteroid injection followed by the Spencer technique, which involves a series of specific manual mobilization maneuvers aimed at improving shoulder mobility and reducing pain.
Study NCT06737978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioSafe Peripheral-5 CTO Crossing System
Description: AngioSafe Peripheral-5 CTO Crossing System is used to help the doctor to pass a guidewire through the blockage in blood vessels below the knee.
Study NCT06741280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profilm Aftas Bucales
Description: The treatment will consist of daily applications of the product as soon as an oral ulcer appears, until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
Study NCT06738433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABB i5
Description: Prebiotic ABB i5 (NextDext®, 5g)
Study NCT06738433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABB C24
Description: ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
Study NCT06738953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention to increase Self Efficacy
Description: Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
Study NCT06738953 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Weekly Recap and Group Discussion on Psychological Experiments
Description: Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
Study NCT06740110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone replacement composite vs standard of care
Description: Bone replacement composite: Before application the Bone replacement composite (size 10 mm) will be mixed with autogenous blood or a saline solution and modelled. Next, the medical device will be applied to the place where teeth extraction is performed.~Standard of care: Before application standard of care (Bio-Oss) will be mixed with autogenous blood or a saline solution and modelled. Next, the standard of care will be applied to the place where teeth extraction is performed. Subsequent application of a collagen membrane (Bio-Gide) will be conducted.
Study NCT06740110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone replacement composite vs standard of care
Description: Bone replacement composite: Before application the Bone replacement composite (size 10 mm) will be mixed with autogenous blood or a saline solution and modelled. Next, the medical device will be applied to the place where teeth extraction is performed.~Standard of care: Before application standard of care (Bio-Oss) will be mixed with autogenous blood or a saline solution and modelled. Next, the standard of care will be applied to the place where teeth extraction is performed. Subsequent application of a collagen membrane (Bio-Gide) will be conducted.
Study NCT06740734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress ball
Description: Sterile Stress ball for pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands.
Study NCT06740734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive touch applications
Description: During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes